Antioxidant therapy in cases of aspirin, prescribed with antiplatelet aim
Thrombosis is recognized as the main complication of coronary heart disease. It is considered as the main cause of death in patients with diabetes mellitus (type I and II). With a view to preventing it, all “diabetics” need antiplatelet therapy, and Aspirin is the drug of choice.
However, in some cases, diabetes mellitus can cause such clotting disorders, in which a thrombogenic predisposition develops. In this situation, standard therapy with Aspirin is ineffective. Acetylsalicylic acid, inactivating type 1, cyclooxygenase, inhibition and treats atherothrombotic disorders in most cases. A2, which manifests thrombogenic properties. But this does not always happen. Some serious cardiovascular complications in patients with diabetes mellitus have a high risk of being associated with Aspirin’s “failure” to block of cyclooxygenase type 1. This is the basis for the study.
As a result, it has been shown that preparations with antioxidant action and dietary nutrition, based on the sufficient use of foods, are rich in antioxidants, can prevent this failure. Such properties have ascorbic acid, tocopherol and polyphenols. Therefore, patients with diabetes should take not only Aspirin, but also complex multivitamin complexes, and also to revise the diet of their own food. Antioxidant therapy in combination with acetylsalicylic acid is a proven and effective way of preventing and possibly treating atherothrombotic complications.
To reveal the predisposition of the organism in increased incomes of antioxidants, if a person suffers from diabetes, it is quite simple – it is necessary to conduct a coagulogram. The state of hypercoagulability against the background of taking Aspirin indicates its “failure” to work (aspirin resistance). Such patients need ascorbic acid, tocopherol and polyphenols. Further studies are needed to determine the most effective dose of these substances.
Antenatalally administered corticosteroids and their effect on daily cortisol management in children
Rapid rates of fetal development in the embryonic period, which are influenced from outside, can affect the further development of the central nervous system. This can lead to a change in mental and physical health. One of the external influences are the glucocorticoids given to the mother during pregnancy in order to prevent premature birth. They are able to re-program the child’s further development. However, it is not yet known in which direction the reprogramming will take place.
Glucococorticoids pass through the blood-brain barrier and bind to target receptors in the central nervous system. Synthetic class of these hormones unlike endogenous easily penetrates the placenta and penetrate directly to the fetus, and, accordingly, to its nervous system.
A common corticosteroid used in obstetrical practice is Betamethasone. It is prescribed to prevent premature termination of pregnancy. In 25% of cases, children, whose mothers took Betamethasone, are born on time. They were the subject of research.
Several studies have examined the antenatal effect of Betamethasone on the circadian rhythm of the hypothalamic-pituitary-adrenal system of children born. The purpose of this study was to determine whether there is a connection between these factors and how strong it is for children born on time.
The first group formed in the study is the children of school age who received in utero Betamethasone and were born on time. The second group – children of the same age, but not receiving antenatal Betamethasone. Circadian release of cortisol was measured in saliva samples at certain daily intervals – immediately after awakening, 30 minutes later, 45 and 60 minutes after sleep, and also in the evening.
It was found that the antenatal appointment of glucocorticosteroids can change the circadian rhythm of the hypothalamic-pituitary-adrenal system in children born after 37 weeks. It has been suggested that the features found can adversely affect the subsequent physical and mental development of such children. In this direction, new studies are being conducted to determine the potential risk to the health of children whose mothers received glucocorticosteroids during the gestational period.